Sander Strengholt
Overview
Explore the profile of Sander Strengholt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
218
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caporali R, Kadakia A, Howell O, Patel J, Milligan J, Strengholt S, et al.
Adv Ther
. 2024 Aug;
41(9):3706-3721.
PMID: 39110310
Introduction: This study compared the clinical effectiveness of switching from tumor necrosis factor inhibitor (TNFi) to upadacitinib (TNFi-UPA), another TNFi (TNFi-TNFi), or an advanced therapy with another mechanism of action...
2.
Taylor P, Choy E, Baraliakos X, Szekanecz Z, Xavier R, Isaacs J, et al.
Rheumatology (Oxford)
. 2023 Aug;
63(2):298-308.
PMID: 37624925
Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction, including cytokines involved in a range of inflammatory diseases, such as RA, psoriasis, atopic dermatitis...
3.
Fleischmann R, Curtis J, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, et al.
Ann Rheum Dis
. 2023 Jun;
82(9):1130-1141.
PMID: 37308218
Objective: Increased risk of serious adverse events (AEs) was reported for tofacitinib relative to tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis (RA) aged ≥50 years enriched for...
4.
Winthrop K, Isaacs J, Calabrese L, Mittal D, Desai S, Barry J, et al.
Semin Arthritis Rheum
. 2022 Nov;
58:152120.
PMID: 36347212
Background: The availability of Janus kinase (JAK) inhibitors has transformed the management of rheumatoid arthritis (RA), helping patients achieve clinical remission. However, the emergence of opportunistic infections (OIs) associated with...
5.
van der Heijde D, Landewe R, Wollenhaupt J, Strengholt S, Terry K, Kwok K, et al.
Rheumatology (Oxford)
. 2020 Oct;
60(4):1708-1716.
PMID: 33057725
Objectives: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We evaluated radiographic progression in tofacitinib-treated patients with RA for up to 3 years in two pooled...
6.
Citera G, Mysler E, Madariaga H, Cardiel M, Castaneda O, Fischer A, et al.
J Clin Rheumatol
. 2020 Aug;
27(8):e482-e490.
PMID: 32826657
Background/objective: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Interstitial lung disease (ILD) is an extra-articular manifestation of RA. We investigated incidence rates of...
7.
Wollenhaupt J, Lee E, Curtis J, Silverfield J, Terry K, Soma K, et al.
Arthritis Res Ther
. 2019 Apr;
21(1):89.
PMID: 30953540
Background: Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up...
8.
Olsen I, Lie E, Vasilescu R, Wallenstein G, Strengholt S, Kvien T
Rheumatology (Oxford)
. 2018 Dec;
58(3):481-491.
PMID: 30508189
Objective: To describe the outcomes of MTX and biologic DMARD (bDMARD) treatment in patients with RA and assess unmet needs in patients who fail treatment, using real-world data from the...
9.
van Vollenhoven R, Lee E, Strengholt S, Mojcik C, Valdez H, Krishnaswami S, et al.
Arthritis Rheumatol
. 2018 Nov;
71(5):685-695.
PMID: 30427585
Objective: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Altered lymphocyte cell counts and a potential association with increased infection rates have been reported in...
10.
Landewe R, Connell C, Bradley J, Wilkinson B, Gruben D, Strengholt S, et al.
Arthritis Res Ther
. 2016 Sep;
18(1):212.
PMID: 27663201
Background: The detection of statistically significant reductions in radiographic progression during clinical studies in patients with rheumatoid arthritis (RA) has become increasingly difficult over the past decade due to early-escape...